NCT05485974View on ClinicalTrials.gov

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Lung CancerNon Small Cell Lung CancerColorectal CancerCancer of PancreasColon CancerSolid TumorCancer
Interventions
DRUG

HBI-2438

KRAS G12C Inhibitor

Trial Locations (14)

33322

BRCR Medical Center, Plantation

44718

Gabrail Cancer Center, Canton

48334

Michigan Center of Medical Research, Farmington Hills

64114

Alliance for Multispecialty Research, LLC, Kansas City

90403

Sarcoma Oncology, Santa Monica

90603

Innovative Clinical Research Institute (ICRI), Whittier

The Oncology Institute of Hope and Innovation, Whittier

90805

The Oncology Institute of Hope and Innovation, Long Beach

91105

The Oncology Institute of Hope and Innovation, Pasadena

91204

The Oncology Institute of Hope and Innovation, Glendale

92024

California Cancer Associates for Research and Excellence, Inc. (cCare), Encinitas

92069

California Cancer Associates for Research and Excellence, Inc. (cCare), San Marcos

92705

The Oncology Institute of Hope and Innovation, Santa Ana

00935

Pan American Center for Oncology Trials (PanOncology Trials), Rio Piedras

All Listed Sponsors
lead

HUYABIO International, LLC.

INDUSTRY